Current evidence on regulated cell death pathways in ovarian cancer is summarized, with emphasis on key regulators, mechanistic links to treatment resistance, potential biomarkers, and the limitations that currently restrict clinical translation.
Abstract
Ovarian cancer is one of the most lethal malignancies of the female reproductive system, largely because many patients are diagnosed at an advanced stage and eventually develop recurrent or treatment-resistant disease. Although cytoreductive surgery, platinum-based chemotherapy, PARP inhibitors, anti-angiogenic agents, and immunotherapy have improved management for selected patients, relapse and drug resistance remain major clinical barriers. Regulated cell death pathways, including apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, disulfidptosis, and autophagy-dependent cell death, are increasingly recognized as contributors to ovarian cancer progression, immune regulation, and therapeutic response. This review summarizes current evidence on these pathways in ovarian cancer, with emphasis on key regulators, mechanistic links to treatment resistance, potential biomarkers, and the limitations that currently restrict clinical translation.
This review systematically outlines the mechanistic underpinnings of multiple major RCD subtypes in OC, with a focused summary of advances in innovative small-molecule compounds targeting these pathways, to provide novel insights and directions for precision therapy in OC.
Yu Liu, Z. Geng, Baofu Jia et al.· Frontiers in Cell and Develo...· 0 citations
Ovarian cancer (OC) is the seventh most prevalent type of cancer in women and one of the most lethal gynecological malignancies, due to the poor prognosis (with a 5-year survival rate of about 50%), the lack of specific clinical symptoms, the absence of effective screening, and the fact that the tumor grows without o...
Aygun R. Mamedova, G. Kopeina, B. Zhivotovsky et al.· Cell Death & Disease· 0 citations
The evolving biological basis of therapeutic resistance is examined and how emerging treatment strategies may be integrated into biologically informed clinical development is discussed to improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.
Jun Kim, Seounghun Kang· Pharmaceuticals· 0 citations
This review summarizes emerging therapeutic strategies for EOC, their mechanisms of action, and their potential to overcome treatment resistance, and covers molecularly targeted therapies, immunotherapies, metabolic and epigenetic approaches, cellular and gene therapies, targeted drug-delivery systems, and locoregional...
Zofia Pietrasik, Mikołaj Kapała, Joanna Pietrasik et al.· Cancers· 0 citations
This review summarizes the status of drug resistance in ovarian cancer, cervical cancer, and endometrial cancer, and elucidates their multi-level drug resistance mechanisms in five aspects: DNA damage repair (DDR) dysregulation, core signaling pathways dysregulation, epigenetic dysregulation, transmembrane drug transpo...
Tiange Xing, Hongxi Liu, Wen-Jing Yu et al.· Journal of Visualized Experi...· 0 citations
This review uncovers recent updates on acquired resistance mechanisms toward standard-of-care treatments driven by deeply rooted heterogeneity and aggressive nature and helps to identify novel strategies targeting pathways to reverse resistance and reduce toxicity in breast cancer patients.
Anuveda Sree Samudrala, G. Nagaraju, RamaRao Malla· Biochimica et biophysica act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
